BioSpace News Archive

An unregistered pest control product identified as “Sure Killer Instant Pressurized Residual Insecticide Spray” has been found in the Canadian marketplace.

The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has launched a new fund to provide assistance to patients who are living with hypercholesterolemia.

BC Platforms, a world leader in genomic data management and analytics, today announced that it has closed a USD $15 million financing round alongside a new commercial collaboration with IQVIA™ (NYSE: IQV).

Clinical Innovations, one of the largest medical device companies dedicated to labor and delivery and neonatal intensive care, has signed a definitive agreement to be acquired by LABORIE Medical Technologies for an enterprise value of $525M.

The Jackson Laboratory (JAX) has received $2.5 million from The Mark Foundation for Cancer Research to study in mice the influence of host genetics on response to immunotherapy.

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has approved ENHERTU® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

Accelerated Approval of Daiichi Sankyo and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) based on the pivotal DESTINY-Breast01 trial that showed clinically meaningful and durable responses

Superiority Trial to Confirm Significantly Improved Clinical Outcomes with Exebacase Added to Antibiotics versus Antibiotics alone to treat Methicillin-Resistant Staph aureus (MRSA) Bacteremia

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointments of life sciences industry veterans, Eric Schmidt, Ph.D., and John Glasspool, to the Company’s Board of Directors, effective December 19, 2019.

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Mark Alles to the Company’s Board of Directors.